BCTX News & Events

BriaCell and its majority-owned subsidiary BriaPro Therapeutics announced that they have entered into a definitive purchase agreement pursuant to which BriaPro has agreed to purchase BriaCell's exclusive license to develop and commercialize Soluble CD80 as a biologic agent for the treatment of cancer and other associated assets. Under the terms of the Purchase Agreement, BriaPro gains the worldwide rights to develop and commercialize sCD80 as a therapeutic agent for the treatment of cancer, while UMBC holds all rights, title and interest in the inventions and the patent, except for certain rights retained by the United States Government. BriaPro will pay 2% royalties to UMBC upon the commercialization of the product plus other development costs. As part of the Transaction, BriaCell will make available to BriaPro up to $3M to fund research and development efforts. Each drawdown under the Credit Facility will be subject to BriaCell's approval regarding the use of funds. As consideration for the transfer of the exclusive license and the Credit Facility, BriaPro will issue to BriaCell 23,972,589 Common Shares at an aggregate value of approximately C$1.18M, increasing BriaCell's interest in BriaPro to approximately 78% post-transaction. The Transaction is expected to close on or around March 12, 2026, subject to certain conditions including (i) approval of the disinterested shareholders of BriaPro, and (ii) receipt of a third-party valuation confirming that the Transaction is occurring at fair market value. In accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, the resolution approving the Purchase Agreement must be approved by a simple majority of votes cast by shareholders, present in person or represented by proxy and entitled to vote at the Meeting, excluding the votes cast by any "interested party." As a 10% shareholder with an interest in the Transaction, BriaCell's shareholdings in BriaPro will be excluded from voting.

BriaCell Therapeutics announces that the independent Data Safety Monitoring Board, DSMB, has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor, CPI, in patients with metastatic breast cancer. Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell's ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration, reflecting the significant unmet medical need in metastatic breast cancer.

BriaCell Therapeutics releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital, temporal lobe, liver, and spinal involvement. Survival details on these and other select patients in its Phase 2 study, along with comparable populations, were previously reported. "The CD8 ImmunoPET images are remarkable, verifying the ability of the BriaCell treatment to activate CD8+ cytotoxic T cells and induce their infiltration into the cancerous tumors. This is key to the mechanism of action of the BriaCell approach and likely play a role in enhancing the long-term survival of patients even after they come off study," stated Dr. William Williams, CEO. A 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer, heavily pretreated with 8 prior lines of therapy, including an antibody-drug conjugate, remains alive 27 months post-enrollment. At baseline, she presented with metastatic involvement of the right orbit, right temporal lobe of the brain and multiple skeletal sites. Following treatment, she achieved complete resolution of the temporal lobe metastasis, substantial improvement in the orbital lesion and stable disease in the bone. She remained on study for 26 months after initiating treatment and receiving 35 cycles of therapy. Images though 20 months for this patient have been previously described. Shown here are updated images through 2 years with measurements superimposed. Bria-IMT treatment resulted in complete resolution of the right temporal lobe lesion and continued regression of the right orbital tumor. A 44-year-old woman with ER+/PR+/HER2- metastatic breast cancer, previously treated with 5 prior lines of therapy. At baseline, she presented with metastases to the spine. She completed 6 cycles of therapy achieving stable disease as her best response and remains in survival follow-up 27 months after study entry. Pre-treatment imaging of cervical lymph nodes with moderate uptake indicating presence of some CD8+ cytotoxic T cells. Post treatment enhancement of cervical lymph nodes indicating immune system activation and increased presence of CD8+ cytotoxic T cells. A 64-year-old woman with ER+/PR-/HER2- metastatic breast cancer, heavily pre-treated with 8 prior lines of therapy, including the antibody-drug conjugate Trodelvy, remains alive 25 months post-enrollment. At baseline, presented with hepatic metastasis. Before BriaCell Treatment: A liver metastasis is "cold," indicating minimal to no CD8+ cytotoxic T cells in the tumor while enlarged lymph nodes show moderate uptake. After BriaCell Treatment: Swelling around the metastasis demonstrates the liver metastasis has become "hot", indicating marked CD8+ cytotoxic T cell infiltration while further lymph node enlargement is consistent with increased activity indicating increased CD8+ T cells.

BriaCell Therapeutics announces new "positive" Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in 9 cases as of their last assessment. Key highlights: 9 of 25 BriaCell patients treated since 2022 remain alive 18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations; No Bria-IMT related discontinuations reported to date; Bria-IMT regimen continues under Fast Track Designation from US FDA